ALK reaches important US milestone
The Danish company Alk-Abello has moved one step closer to the US market, as its partner Merck has delivered a registration application to the FDA.
by Henrik Tüchsen
Late last week ALK’s US partner, Merck & Co., sent an application for marketing approval for ALKs drug against grass pollen allergy to the FDA – an extremely important milestone to the Danish company – ALK reveals in a stock market release.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app
.jpg&w=384&q=75){kind=logo}
